Karen Chachu, MD
Gastroenterology · Raleigh, NCNPI 1871727396
Payments from drug & device makers
What this record shows
This record is dominated by consulting fees: $13,900 of the $16,484 with a category attached, or 84.3%. Janssen Scientific Affairs, LLC accounts for 91.9% of it on its own, with 2 other manufacturers making up the rest. Reporting peaked in 2024 at $15,145 and has fallen 99.2% since, to $125 in 2025.
Across 17 payments — averaging $969.63 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Janssen Scientific Affairs, LLC$15K
- Janssen Research & Development, LLC$1K
- AbbVie$125
Across 31 payments — averaging $2690.48 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.
- Janssen Research & Development, LLC$83K
What the payments were for
- Consulting fees$13,90084%
- Travel & lodging$2,06012%
- Food & beverage$5243%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Janssen Scientific Affairs, LLC | 9 | $15,145 |
| Janssen Research & Development, LLC | 7 | $1,214 |
| AbbVie | 1 | $125 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
How this compares
$16,484 in reported general payments places this provider in the 85th percentile of 610 gastroenterology providers in North Carolina.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| StelaraUstekinumab | 27 | $726,565 |
| Mesalamine | 16 | $15,433 |
| Mesalamine ErMesalamine | 19 | $2,616 |
| Sod Sulf-Potass Sulf-Mag SulfSodium, Potassium,mag Sulfates | 23 | $1,722 |
| Gavilyte-GPeg3350/Sod Sulf,bicarb,cl/Kcl | 69 | $1,208 |
| Famotidine | 28 | $381 |
| Dicyclomine Hcl | 16 | $356 |
| Peg-3350 And ElectrolytesPeg3350/Sod Sulf,bicarb,cl/Kcl | 22 | $351 |
| Omeprazole | 21 | $274 |
| Esomeprazole Magnesium | 13 | $254 |
| Pantoprazole Sodium | 15 | $212 |
Paid to pharmacies, not to this prescriber.
Other gastroenterology in Raleigh
- Rig PatelRaleigh$94K
- Alyson JohnsonRaleigh$52K
- Henry VanpalaRaleigh$40K
- Stephen DealCharlotte$945K
- Fred FowlerCharlotte$932K
- Paul WatkinsChapel Hill$876K
- Nilesh LodhiaCharlotte$735K
- Evan DellonChapel Hill$431K
- Robert ReindollarSalisbury$430K
- Andrew StormWinston Salem$426K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.